Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel

Journal of the National Cancer Institute

Volumn 88, Issue 18, 1996, Pages 1308-1314

  Milross, Christopher G ^a   Mason, Kathryn A ^a   Hunter, Nancy R ^a   Chung, Woong Ki ^a   Peters, Lester J ^a   Milas, Luka ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER TRANSPLANTATION; DRUG EFFECT; LIVER CELL CARCINOMA; LYMPHOMA; MALE; MALIGNANT NEOPLASTIC DISEASE; MITOSIS; MOUSE; NONHUMAN; OVARY CANCER; SALIVARY GLAND CANCER; SARCOMA;

EID: 0029745777     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/88.18.1308     Document Type: Article

References (49)

1. Dustin P. Microtubules. Sci Am 1980;243:66-76.
2. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979;277:665-7.
3. Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci U S A 1980;77:1561-5.
4. Tishler RB, Geard CR, Hall EJ, Schiff PB. Taxol sensitizes human astrocytoma cells to radiation. Cancer Res 1992;52:3495-7.
5. Liebmann J, Cook JA, Lipschultz C, Teague D, Fisher J, Mitchell JB. The influence of Cremophor EL on the cell cycle effects of paclitaxel (Taxol) in human tumor cell lines. Cancer Chemother Pharmacol 1994;33:331-9.
6. Bhalla K, Ibrado AM, Tourkina E, Tang C, Mahoney ME, Huang Y, Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells. Leukemia 1993;7:563-8.
7. Gangemi RM, Tiso M, Marchetti C, Severi AB, Fabbi M. Taxol cytotoxicity on human leukemia cell lines is a function of their susceptibility to programmed cell death. Cancer Chemother Pharmacol 1995;36:385-92.
8. Milas L, Hunter NR, Kurdoglu B, Mason KA, Meyn RE, Stephens LC, et al. Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with taxol. Cancer Chemother Pharmacol 1995;35:297-303.
9. Milross CG, Peters LJ, Hunter NR, Mason KA, Milas L. Sequence-dependent antitumor activity of paclitaxel (Taxol) and cisplatin in vivo, Int J Cancer 1995;62:599-604.
10. Terasima T, Tolmach LJ. Variations in several responses of HeLa cells to x-irradiation during the cell cycle. Biophys J 1963;3:11-33.
11. Sinclair WK, Morton RA. X-ray sensitivity during the cell generation cycle of cultured Chinese hamster cells. Radiat Res 1966;29: 450-74.
12. Withers HR, Mason K, Reid BO, Dubravsky N, Barkley HT Jr, Brown BW, et al. Reponse of mouse intestine to neutrons and gamma rays in relation to dose fractionation and division cycle. Cancer 1974;34:39-47.
13. Choy H, Rodriguez FF, Koester S, Hilsenbeck S, Von Hoff DD. Investigation of taxol as a potential radiation sensitizer. Cancer 1993;71: 3774-8.
14. Steren A, Sevin BU, Perras J, Angioli R, Nguyen H, Guerra L, et al. Taxol sensitizes human ovarian cancer cells to radiation. Gynecol Oncol 1993;48:252-8.
15. Liebmann J, Cook JA, Fisher J, Teague D, Mitchell JB. In vitro studies of Taxol as a radiation sensitizer in human tumor cells. J Natl Cancer Inst 1994;86:441-6.
16. Minarik L, Hall EJ. Taxol in combination with acute and low dose rate irradiation [see comment citation in Medline]. Radiother Oncol 1994;32:124-8.
17. Liebmann J, Cook JA, Fisher J, Teague D, Mitchell JB. Changes in radiation survival curve parameters in human tumor and rodent cells exposed to paclitaxel (Taxol). Int J Radial Oncol Biol Phys 1994;29:559-64.
18. Milas L, Hunter NR, Mason KA, Kurdolglu B, Peters LJ. Enhancement of tumor radio-response of a murine mammary carcinoma by paclitaxel. Cancer Res 1994;54:3506-10.
19. Milas L, Hunter NR, Mason KA, Milross CG, Saito Y, Peters LJ. Role of reoxygenation in induction of enhancement of tumor radio-response by paclitaxel. Cancer Res 1995;55: 3564-8.
20. Milas L, Hunter N, Mason K, Withers HR. Immunological resistance to pulmonary metastases in C3Hf-Bu mice bearing syngeneic fibrosarcoma of different sizes. Cancer Res 1974;34:61-71.
21. Milas L, Wike J, Hunter N, Volpe J, Basic I. Macrophage content of murine sarcomas and carcinomas: associations with tumor growth parameters and tumor radiocurability. Cancer Res 1987; 47:1069-75.
22. Suit H, Allam A, Allalunis-Turner J, Brock W, Girinsky T, Hill S, et al. Is tumor cell radiation resistance correlated with metastatic ability? Cancer Res 1994; 54:1736-41.
23. Meyn RE, Stephens LC, Hunter NR, Milas L. Apoptosis in murine tumors treated with chemotherapy agents. Anticancer Drugs 1995; 6:443-50.
24. Kallman RF, editor. Rodent tumor models in experimental cancer therapy. New York: Pergamon Press, 1987.
25. Zar JH. Biostatistical analysis. 2nd ed. Englewood Cliffs (NJ): Prentice-Hall, 1984.
26. Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, et al. Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991;83:1797-805.
27. Gianni L, Munzone E, Capri G, Villani F, Spreafico C, Tarenzi E, et al. Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines [see comment citation in Medline]. J Natl Cancer Inst 1995;87:1169-75.
28. McGuire WP, Rowinksy EK, Rosenshein NB, Grumbine FC, Ettinger DS, Armstrong DK, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989;111:273-9.
29. Thigpen JT, Blessing JA, Ball H, Hummel SJ, Barrett RJ. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J Clin Oncol 1994;12:1748-53.
30. Kohn EC, Sarosy G, Bicher A, Link C, Christian M, Steinberg SM, et al. Dose-intense Taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer. J Natl Cancer Inst 1994;86:18-24.
31. Reichman BS, Seidman AD, Crown JP, Heelan R, Hakes TB, Lebowohl DE, et al. Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1993;11:1943-51.
32. Ettinger DS, Finkelstein DM, Sarma RP, Johnson DH. Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 1995;13:1430-5.
33. Roth BJ, Dreicer R, Einhorn LH, Neuberg D, Johnson DH, Smith JL, et al. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 1994;12:2264-70.
34. Ajani JA, Ilson DH, Daugherty K, Pazdur R, Lynch PM, Kelsen DP. Activity of Taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 1994;86:1086-91.
35. Forastiere AA. Current and future trials of Taxol (paclitaxel) in head and neck cancer. Ann Oncol 1994;5 Suppl 6:S51-4.
36. Murphy WK, Fossella FV, Winn RJ, Shin DM, Hynes HE, Gross HM, et al. Phase II study of Taxol in patients with untreated advanced non-small-cell lung cancer [see comment citation in Medline]. J Natl Cancer Inst 1993;85:384-8.
37. Chamberlain MC, Kormanik P. Salvage chemotherapy with paclitaxel for recurrent primary brain tumors. J Clin Oncol 1995;13:2066-71.
38. Legha SS, Ring S, Papadopoulos N, Raber M, Benjamin RS. A phase II trial of Taxol in metastatic melanoma. Cancer 1990;65:2478-81.
39. Einzig AI, Hochster H, Wiernik PH, Trump DL, Dutcher JP, Garowski E, et al. A phase II study of Taxol in patients with malignant melanoma. Invest New Drugs 1991;9:59-64.
40. Gian V, Lynch J, McCarley D, Johnson T. Taxol in the treatment of recurrent or metastatic soft tissue or osteosarcoma. Proc ASCO 1995;14:516.
41. Thigpen T, Vance RB, Khansur T. The platinum compounds and paclitaxel in the management of carcinomas of the endometrium and uterine cervix. Semin Oncol 1995;22(5 Suppl 12):67-75.
42. Roth BJ, Yeap BY, Wilding G, Kasimis B, McLeod D, Loehrer PJ. Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group. Cancer 1993;72:2457-60.
43. Elomaa L, Joensuu H, Kulmala J, Klemi P, Grenman R. Squamous cell carcinoma is highly sensitive to Taxol, a possible new radiation sensitizer. Acta Otolaryngol (Stockh) 1995; 115:340-4.
44. Rowinsky EK, Donehower RC, Jones RJ, Tucker RW. Microtubule changes and cytotoxicity in leukemic cell lines treated with Taxol. Cancer Res 1988;48:4093-100.
45. Roberts JR, Allison DC, Donehower RC, Rowinsky EK. Development of polyploidization in Taxol-resistant human leukemia cells in vitro. Cancer Res 1990;50:710-6.
46. Meyn RE, Stephens LC, Ang KK, Hunter NR, Brock WA, Milas L, et al. Heterogeneity in the development of apoptosis in irradiated marine tumours of different histologies. Int J Radiat Biol 1993;64:583-91.
47. Kerr JF, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy [published erratum appears in Cancer 1994;73:3108]. Cancer 1994;73:2013-26.
48. Raff MC. Social controls on cell survival and cell death. Nature 1992;356:397-400.
49. Wheeler JA, Stephens LC, Tornos C, Eifel PJ, Ang KK, Milas L, et al. ASTRO Research Fellowship: apoptosis as a predictor of tumor response to radiation in stage IB cervical carcinoma. American Society for Therapeutic Radiology and Oncology. Int J Radiat Biol Oncol Phys 1995;32:1487-93.